These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 16446376

  • 1. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B, Sánchez-Alvarez J, García-Mendez E, Sabriá M, Santos J, Pallarés R, Twynholm M, Dal-Ré R, 620 Clinical Study Group.
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM, Garau J, Jacobs MR, Wynne B, Twynholm M, Berkowitz E.
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [Abstract] [Full Text] [Related]

  • 3. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
    Garau J, Twynholm M, Garcia-Mendez E, Siquier B, Rivero A, 557 Clinical Study Group.
    J Antimicrob Chemother; 2003 Nov; 52(5):826-36. PubMed ID: 14563899
    [Abstract] [Full Text] [Related]

  • 4. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
    File TM, Lode H, Kurz H, Kozak R, Xie H, Berkowitz E, 600 Study Group.
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.
    Sethi S, Breton J, Wynne B.
    Antimicrob Agents Chemother; 2005 Jan; 49(1):153-60. PubMed ID: 15616290
    [Abstract] [Full Text] [Related]

  • 6. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [Abstract] [Full Text] [Related]

  • 7. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
    Petitpretz P, Chidiac C, Soriano F, Garau J, Stevenson K, Rouffiac E, 556 Clinical Study Group.
    Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetically enhanced amoxicillin/clavulanate (2,000/125 mg) in acute bacterial rhinosinusitis caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    Anon JB, Ferguson B, Twynholm M, Wynne B, Berkowitz E, Poole MD.
    Ear Nose Throat J; 2006 Aug; 85(8):500, 502, 504 passim. PubMed ID: 16999056
    [Abstract] [Full Text] [Related]

  • 9. Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae.
    Garau J.
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():28-35. PubMed ID: 14759231
    [Abstract] [Full Text] [Related]

  • 10. The efficacy and safety of amoxicillin-clavulanic acid 1000/125mg twice daily extended release (XR) tablet for the treatment of bacterial community-acquired pneumonia in adults.
    Prabhudesai PP, Jain S, Keshvani A, Kulkarni KP.
    J Indian Med Assoc; 2011 Feb; 109(2):124-7. PubMed ID: 21888181
    [Abstract] [Full Text] [Related]

  • 11. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM, Mandell LA, Tillotson G, Kostov K, Georgiev O.
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [Abstract] [Full Text] [Related]

  • 12. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
    Rosón B, Carratalà J, Tubau F, Dorca J, Liñares J, Pallares R, Manresa F, Gudiol F.
    Microb Drug Resist; 2001 Jul; 7(1):85-96. PubMed ID: 11310807
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic options for pneumococcal pneumonia in Turkey.
    Oncu S, Erdem H, Pahsa A.
    Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
    [Abstract] [Full Text] [Related]

  • 14. [Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults].
    Trémolières F, Mayaud C, Mouton Y, Weber P, Dellatolas F, Caulin E.
    Pathol Biol (Paris); 2005 Jun; 53(8-9):503-10. PubMed ID: 16181747
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
    Fogarty C, Torres A, Choudhri S, Haverstock D, Herrington J, Ambler J.
    Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
    [Abstract] [Full Text] [Related]

  • 16. Risk factors and clinical outcomes of penicillin resistant S. pneumoniae community-acquired pneumonia in Khon Kaen, Thailand.
    Reechaipichitkul W, Assawasanti K, Chaimanee P.
    Southeast Asian J Trop Med Public Health; 2006 Mar; 37(2):320-6. PubMed ID: 17124993
    [Abstract] [Full Text] [Related]

  • 17. Antibiotics for childhood community-acquired pneumonia in a region with a high prevalence of penicillin non-susceptible Streptococcus pneumoniae.
    Lee WK, Young BW.
    J Antimicrob Chemother; 2005 Sep; 56(3):603-5. PubMed ID: 16040621
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections.
    Balgos AA, Rodriguez-Gomez G, Nasnas R, Mahasur AA, Margono BP, Tinoco-Favila JC, Sansores-Martinez RH, Hassan M, Beppo O, Wongsa A, Cukier A, Vargas F.
    Int J Clin Pract; 1999 Sep; 53(5):325-30. PubMed ID: 10695094
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.
    File TM.
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S131-4. PubMed ID: 18029151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.